WY-45233
WY-45233 is a synthetic compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective agonist of the peroxisome proliferator-activated receptor (PPAR) family, specifically targeting the PPAR-δ subtype. This receptor is involved in the regulation of lipid metabolism, energy homeostasis, and inflammation.
Pharmacology[edit | edit source]
WY-45233 acts as a selective agonist for the PPAR-δ receptor. PPAR-δ is one of the three types of PPARs, the others being PPAR-alpha and PPAR-gamma. These receptors are nuclear hormone receptors that regulate the expression of genes involved in various metabolic processes.
Mechanism of Action
Upon binding to PPAR-δ, WY-45233 activates the receptor, which then forms a heterodimer with the retinoid X receptor (RXR). This complex binds to specific response elements in the DNA, leading to the transcription of genes involved in fatty acid oxidation, energy expenditure, and anti-inflammatory responses.
Therapeutic Potential
Due to its role in modulating lipid metabolism and inflammation, WY-45233 has been investigated for its potential use in treating metabolic disorders such as dyslipidemia, obesity, and type 2 diabetes mellitus. Additionally, its anti-inflammatory properties suggest potential applications in cardiovascular disease and neurodegenerative disorders.
Research and Development[edit | edit source]
Research on WY-45233 is ongoing, with studies focusing on its efficacy and safety profile in various animal models and clinical trials. The compound's ability to improve lipid profiles and enhance insulin sensitivity has been a significant area of interest.
Safety and Side Effects[edit | edit source]
As with any pharmacological agent, the safety profile of WY-45233 is critical. Preclinical studies have shown that it is generally well-tolerated, but further research is needed to fully understand its long-term effects and potential side effects in humans.
Also see[edit | edit source]
- Peroxisome proliferator-activated receptor
- PPAR-delta
- Lipid metabolism
- Nuclear receptor
- Metabolic syndrome
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
